????: 2020??7??7???? 09:00-16:00
????: 媛�?⑤┃?�?숆탳 ?깆쓽?뚭? 留덈━?꾪?
????: ?섑삊?됱젏 4??/p>
?ъ쟾?깅줉留덇컧?? 2020??6??26??湲?
?덊럹?댁? : http://www.kbcs.or.kr/abstract/2020_sympo17/info.html
?꾨줈洹몃옩 ?덈궡
| Time |
Topic |
Speaker |
| 09:00-09:10 |
Welcome Remarks |
|
| 09:10-10:20 |
Session I : Hormone Receptor Positive and HER2 Negative Breast Cancer Update |
醫뚯옣: ?뺤? (?곗꽭?섎?) |
| 09:10-09:30 |
Adjuvant endocrine therapy: Optimal duration, switching from tamoxifen to AI |
?ㅽ쁽議?(?꾨턿?섎?) |
| 09:30-09:50 |
CDK4/6 inhibitor in metastatic breast cancer |
?닿꼍?� (?댄솕?섎?) |
| 09:50-10:10 |
PI3K inhibitor and AKT inhibitor in metastatic breast cancer |
?닿렐??(援?┰?붿꽱?? |
| 10:10-10:20 |
Dicussion |
| 10:20-10:40 |
Coffee Break |
| 10:40-11:50 |
Session II : HER2 Positive Breast Cancer Update |
醫뚯옣: 諛뺤뿰??(?깃퇏愿�?섎?) |
| 10:40-11:00 |
Optimal neoadjuvant/adjuvant systemic therapy |
源�?쒖“ (?쒖쿇?μ쓽?�) |
| 11:00-11:20 |
Neoadjuvant/adjuvant therapy for small HER2 positive breast cancer |
?덊씗寃?(媛�泥쒖쓽?�) |
| 11:20-11:40 |
Optimal systemic therapy for HR+HER2+ metastatic breast cancer |
?댁닔??(?숈븘?섎?) |
| 11:40-11:50 |
Dicussion |
| 11:50-12:20 |
?쒓뎅?좊갑?뷀븰??珥앺쉶 |
| 11:20-13:20 |
Lunch |
| 13:20-14:45 |
Session III : Triple Negative Breast Cancer Update |
醫뚯옣:?먯＜???곗꽭?섎?) |
| 13:20-13:35 |
Optimal neoadjuvant/adjuvant systemic therapy |
?댁??� (媛�?⑤┃?섎?) |
| 13:35-13:50 |
PARP Inhibitor in metastatic breast cancer |
?꾩꽍??(?쒖슱?섎?) |
| 13:50-14:05 |
Immune checkpoint inhibitor in metastatic breast cancer |
諛뺤씤??(怨좊젮?섎?) |
| 14:05-14:15 |
Dicussion |
| 14:15-14:35 |
Coffee Break |
| 14:35-16:00 |
Session IV : Oligometastasis (except CNS area) |
醫뚯옣: ?쒖썝???쒖슱?섎?) |
| 14:35-14:55 |
Role of surgery for lung metastasis in breast cancer patients |
?닿렐??(?몄궛?섎?) |
| 14:55-15:15 |
Role Radiotherapy for oligometastasis in breast cancer patients (including radiosurgery) |
?≪쭊??(媛�?⑤┃?섎?) |
| 15:15-15:35 |
Systemic therapy before/after local therapy |
臾몄슜??(李⑥쓽怨쇳븰?�) |
| 15:35-15:50 |
Dicussion |
| 15:50-16:00 |
Closing Remarks |